195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)

Journal article

Open access

Peer reviewed

L. Paz-Ares, S. Rubin, Y. Zhao, L. Xu, A. Samkari and M. Awad

Journal of thoracic oncology, v 13(4), pp S116-S117

Apr 2018

Files and links (1)

url

https://doi.org/10.1016/S1556-0864(18)30468-4View

Published, Version of Record (VoR) Open

7 Record Views

Title: 195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)
Creators: L. Paz-Ares - Research Institute Hospital 12 de Octubre
S. Rubin - Incyte (United States)
Y. Zhao - Incyte (United States)
L. Xu
A. Samkari - Merck & Co., Inc., Rahway, NJ, USA (United States)
M. Awad - Dana-Farber Cancer Institute
Publication Details: Journal of thoracic oncology, v 13(4), pp S116-S117
Publisher: Elsevier
Resource Type: Journal article
Language: English
Academic Unit: Pediatrics
Web of Science ID: WOS:000436557600189
Other Identifier: 991021838696104721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web of Science research areas: Oncology; Respiratory System